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ABSTRACT
Ibogaine is a psychoactive alkaloid contained in the West African plant Tabernanthe iboga. Although
preliminary, evidence suggests that ibogaine could be effective in the treatment of certain substance use
disorders, speciﬁcally opioid use disorder. This narrative review concentrated on the pharmacological,
cultural and psychological aspects of ibogaine that contribute to its reputed effectiveness with a speciﬁc
focus on the ibogaine state of consciousness. Although the exact pharmacological mechanisms for
ibogaine are still speculative, the literature highlighted its role as an NMDA antagonist in the effective
treatment of substance use disorders. The cultural aspects associated with the use of ibogaine pose
questions around the worldview of participants as experienced in the traditional and western contexts,
which future research should clarify. From a psychological perspective, the theory that the ibogaine state
of consciousness resembles REM sleep is questionable due to evidence that indicated ibogaine supressed
REM sleep, and contradictory evidence in relation to learning and memory. The suggested classiﬁcation
of the ibogaine experience as oneirophrenic also seems inadequate as it only describes the ﬁrst phase of
the ibogaine experience. The ibogaine experience does however present characteristics consistent with
holotropic states of consciousness, and future research could focus on exploring and potentially classifying the state of consciousness induced by ibogaine as holotropic.
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Ibogaine, non-ordinary states of consciousness, holotropic states, Bwiti

INTRODUCTION
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According to the United Nations (UN) World Drug Report (2020), it is estimated that in
2018, 58 million people worldwide were using opioids. Opioids are responsible for approximately two-thirds of acute deaths resulting from substance use disorders, with an estimated
11 million people injecting on a daily basis. The recent rise in opioid-related deaths can be
attributed to the non-medical use of prescription opioids, an increase in the use of heroin and
the emergence of synthetic opioids such as fentanyl in illicit drug markets.
Against the background of the current scientific renaissance in psychedelics and using
previously prohibited psychoactive substances as therapeutic agents (Bright, Williams, &
Caldicott, 2017), ibogaine presents an alternative in the treatment of opioid use disorder.
Ibogaine is one of the naturally occurring psychoactive alkaloids found in the West African
plant Tabernanthe iboga (iboga), reputed for effectively treating substance use disorders
(Kaplan, Ketzer, De Jong, & De Vries, 1993; Sisko, 1993; Touchette, 1993). Iboga is an
angiosperm from the Apocynaceae family (Mazoyer et al., 2013) that grows naturally in
Western and Central Africa. The roots contain a number of psychotropic indole alkaloids,
with the bark containing between 5 and 6% ibogaine. Iboga rootbark is generally dried and
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ingested in thin strips, or ground into a powder. Taken in
low quantities (e.g., less than 50 mg), ibogaine is a psychostimulant, suppressing appetite and increasing feelings of
euphoria. Higher doses of ibogaine (e.g., between 100 mg
and 1 g) induce a trance-like state that can include visual
and auditory hallucinations, ataxia and an altered perception
of time (Alper, Lotsof, & Kaplan, 2008; Mazoyer et al., 2013).
Ibogaine can be ingested orally as a purified form of
ibogaine hydrochloride (HCL), which is obtained by
extracting ibogaine from the rootbark and removing other
impurities and alkaloids. Ibogaine can also be semi-synthetically converted from voacangine, an indole alkaloid
contained within the Voacanga africana plant, using a twostep protocol consisting of ester saponiﬁcation followed by
acidiﬁcation for subsequent decarboxylation (Krengel,
Milangos, Reyes-Lezama, & Reyes-Chilpa, 2019). Ibogaine
can also be obtained by a total alkaloid extraction from iboga
rootbark that contains between 15 and 20% total alkaloids,
of which half is ibogaine. In addition, ibogaine can be taken
as the crude plant rootbark. Rootbark may contain between
1 and 6% ibogaine depending on its age and other agronomic factors (Lotsof & Wachtel, 2003).
A synthetic analogue of ibogaine was developed in 1996,
18-methoxycoronaridine (18-MC). The aim of 18-MC was
to create a non-psychoactive medicine that retained ibogaine’s reported ability to effectively eliminate opioid
withdrawal. In 2013, Savant HWP received a grant of $6.5
million from the USA National Institute on Drug Abuse
(NIDA) for preclinical development of 18-MC. At the time
of writing, a Phase 1 human clinical trial of 18-MC had
been completed and planning for Phase 2a clinical research
was allegedly underway (MindMed completes dosing,
2020).
In case reports and observational studies, ibogaine doses
have varied from 15 to 25 mg/kg for HCL and from 3 to 5 g
for the total alkaloid extract (for review, see Schep, Slaughtera, Galeab, & Newcombec, 2016). Lethal doses vary from
between 145 and 175 mg/kg in animal models, depending on
the route of administration (for review, see Schep et al.,
2016). A full therapeutic dose (of between 15 and 20 mg/kg),
or ﬂood dose as it is referred to by Lotsof and Wachtel
(2003), produces what appear to be three distinct phases in
the psychological effects, marked by common elements in
the experience (Alper, 2001).
The first is the acute phase, with onset starting between
one and 3 h following oral ingestion. Physical sensations
include dizziness, a lack of coordination, nausea and vomiting. During this phase, participants report wanting to
remain as still as possible, with some reporting a sensitivity
to light and noise (Lotsof, 1995; Naranjo, 1969, 1973).
Participants also experience dryness of the mouth, increased
perspiration, and an increase in pulse rate (Popik et al.,
1995). A review by Alper (2001) derived from interviews
with participants and treatment guides, suggested that the
visual experience during the acute phase involved revisiting
memories as well as contact with seemingly transcendent
beings. The second phase is the reﬂective phase,
commencing approximately 4 to 8 h after ingestion. The
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emotional tone of this phase is reportedly neutral and
reﬂective, and the participants interviewed by Alper (2001)
continued to focus on the internal experience. The ﬁnal
phase is the residual stimulation phase, beginning approximately 12–24 h after ingestion. During this phase, Alper
(2001) documented a return of attention to the external
environment, and the intensity of the psychoactive experience gradually lessening, with some participants reporting a
reduced need for sleep in the days or weeks to follow.
The Manual for Ibogaine Therapy (Lotsof & Wachtel,
2003) was published to offer guidelines for participants and
practitioners regarding the screening, safety, monitoring and
aftercare of ibogaine. The manual recommended medical
evaluation of liver and kidney function tests as well as an
electrocardiogram (ECG) prior to treatment. It also offered
various recommendations on dosage, from high dosages to
smaller and staggered dosages over time, and highlighted the
importance of aftercare, suggesting integration of the ibogaine experience through continued psychotherapy.
Following the publication of this manual, the Global Ibogaine Therapy Alliance published clinical guidelines for
ibogaine-assisted detoxiﬁcation (Dickinson et al., 2015) that
detail the context of care, procedures for intake, treatment,
dosing, intervention and discharge. It also provided
comprehensive information on medications and psychoactive substances that have interactions with ibogaine, such as
selective serotonin reuptake inhibitors (SSRIs), benzodiazepines, alcohol, steroids and stimulants. The guidelines
included a bill of rights for the ibogaine participant, and a
list of recommended equipment and useful adjunct medications for practitioners.
Ibogaine has been considered both a psychedelic and an
entheogen (Bogenschutz & Johnson, 2016; Ott, 1996). According to Grinspoon and Bakalar (1997) and Nichols
(2016), psychedelics do not cause physical dependence,
craving or major physiological disturbances, delirium,
disorientation or amnesia. In addition, psychedelics, from
the Latin roots meaning mind-manifesting, reliably produce
thought, mood and perceptual changes otherwise rarely
experienced except in dreams, contemplative and religious
exaltation, ﬂashes of vivid involuntary memory and acute
psychosis. In contrast, entheogens have been described as
psychoactive substances ingested in the religious context for
a spiritual purpose (Ott, 1996). According to this classiﬁcation, ibogaine’s well-document use in the Bwiti tradition
would render it an entheogen. The Latin roots of entheogen
translate to become divine within (Ott, 1996, p. 205) and the
term describes the shamanic and mystical states experienced
through the ingestion of substances, which also correlate
with descriptions of the ibogaine experience.
The ibogaine state of consciousness has also been
described as oneirophrenic (Brown, 2013; Davis, Barsuglia,
Windham-Herman, Lynch, & Polanco, 2017; Lotsof &
Alexander, 2001), meaning waking dream – a dream state
occurring outside of normal sleep. Much like psychedelic
experiences, ibogaine can induce vivid imagery experienced
with eyes both open and closed, ranging from geometric
patterns to a wide variety of representational images that are
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often hypnagogic. This dream-like experience typically only
constitutes the ﬁrst phase of the ibogaine experience (Alper,
2001). Entheogens such as ibogaine not only induce a nonordinary state of consciousness that can include mystical or
peak experiences (Winkelman, 2014), they are also thought
to deliver profound insights and induce lasting change in
patterns of thought, emotional responses and behaviour
(Hoffer, 1967 as cited by Bogenschutz & Johnson, 2016).

METHODOLOGY
A narrative review was conducted that considered the
pharmacological, cultural and psychological aspects of ibogaine, with a specific focus on understanding the ibogaine
state of consciousness. In doing so, we aimed to provide a
synthesised description of the landscape that describes ibogaine treatment. The first author (MU) began by immersing
herself in the extant literature using mapping to understand
the broad landscape that describes ibogaine treatment. In
doing so, a visual representation of the literature was
created, in which categories emerged and gaps were identified from which to commission the primary search. This was
an ongoing iterative process.
The literature search was conducted between March 2019
and March 2020. The first step involved the identification of
themes, followed by key words, and used nesting techniques
to research key words and phrases. The word ibogaine was
initially used to search across several databases. Information
was grouped under the headings of pharmacological, cultural
and psychological. Keywords and phrases were entered and
searched in the following databases: ResearchGate, Sage,
JSTOR, Science Direct, NCBI, Semantic Scholar, Wiley Online Library and the Canterbury Christ Church University
library. Given the relative limited availability of academic
literature on ibogaine, as compared with other psychedelics
such as psilocybin and ayahuasca, literature from the emergence of ibogaine in empirical research from 1969 onwards
was considered and included where information was relevant. Titles and abstracts were read to screen for relevance.
The criteria for inclusion included relevance to the topic,
and incorporation of hypotheses that validated or contradicted known information or contributed new information.
Articles were also included if they demonstrated differences
between preclinical data and observational data. Articles
were excluded based on their relevance, credibility of the
information provided or if we deemed they did not add new
information to existing reviews. A critical review of the
remining literature followed, which aimed to evaluate and
synthesise the existing literature and models to review the
conceptual contribution of each study.

RESULTS
A total of 60 articles were identified and read in their entirety. Twenty-seven articles were subsequently excluded,
with the remaining 33 articles highlighting particular themes
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or ideas not yet covered by the existing literature, with
attention given to literature that contributed to the relevance
of the ibogaine state of consciousness. Articles were categorised according to the mechanism of action, the set-andsetting, and the psychological aspects as contributing factors
to the effectiveness of ibogaine. Emphasis was placed on the
psychological aspects as a potential area requiring additional
research, with the aim of mapping existing literature that
defines the ibogaine state of consciousness.

Pharmacological aspects that contribute to the
effectiveness of ibogaine
Pharmacological profile. Ibogaine’s psychopharmacological
proﬁle in preclinical data included interactions with multiple
neurotransmitter systems related to substance use, including
glutamatergic, sigma, nicotinic, mu- and kappa-opioid,
dopaminergic and serotonergic systems (Alper, 2001; Floresta et al., 2019). Ibogaine is not a conventional dopamine or
opioid agonist or antagonist, or a monoamine reuptake inhibitor. While the exact mechanism for ibogaine is still
speculative, preclinical studies have suggested antagonism of
N-methyl-D-aspartate (NMDA) receptors within the glutamatergic system (Alper, 2001; Popik, Layer, & Skolnick,
1994, 1995) since ibogaine inhibited the binding of the
NMDA antagonist MK801 to the NMDA receptor complex
(Popik et al., 1994) in animal models. Further, the use of
NMDA antagonists potentially offers a new paradigm for the
treatment of substance use disorders. A review by Rodger
(2018) of preclinical models and preliminary clinical trials
suggested that NMDA receptor antagonism could be associated with the unlearning of ﬁxed perceptions and responses, which could include the cravings and responses to
environmental cues associated with substance use disorders.
In animal models, the pharmacological and behavioural effects of ibogaine included a decrease in the self-administration of morphine and cocaine, reduced morphine
withdrawal syndrome, and a decrease in locomotor activity,
cardiovascular effects and tremor (Popik et al., 1995).
Ibogaine’s main metabolite, noribogaine, was discovered
by Mash (1998). Both ibogaine and noribogaine are mainly
metabolised by cytochrome P4502D6 (CYP2D6) enzymes in
the liver (Alper, 2001; Schenberg et al., 2016), and to a lesser
extent other isoforms (Koenig & Hilber, 2015; Obach, Pablo,
& Mash, 1998). Noribogaine displays a slow pharmacokinetic clearance rate in humans, demonstrating plasma
elimination half-lives of approximately 28–49 h (Glue et al.,
2015; Mash et al., 2000). In addition, noribogaine can be
detected for several days in the blood following ingestion in
part due to enterohepatic circulation (Glue et al., 2015) and
its lipophilic proﬁle (Hough, Pearl, & Glick, 1996; Kontrimaviciute et al., 2006). The delayed elimination of noribogaine is believed by Mash (2018) to contribute greatly to
the therapeutic effects of ibogaine treatment, proposing that
noribogaine continues to act as a highly effective antidepressant to alleviate cravings well after ibogaine has been
eliminated.
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Ibogaine as treatment for opioid use disorder. Four observational studies in humans were identified that demonstrate
a representative cross section of the effectiveness of ibogaine
for opioid dependency. The first was a study of seven participants from a vagrant community in Amsterdam by
Sheppard (1994) who were administered a single dose of
between 11.7 and 25 mg/kg ibogaine with an 18-week followup period. One participant (14%) recontinued substance use
after two days, while two individuals (28%) from the
remaining six participants relapsed after 10 and 12 weeks
respectively. One (14%) reverted to intermittent heroin use
eight months after the study, and the remaining three (43%)
appeared to have remained substance free at the 18-week
follow-up. Second, in a study by Alper et al. (1999) that
focused on opioid detoxiﬁcation, 33 opioid dependent participants were administered between 6 and 29 mg/kg ibogaine in non-medical settings under open label conditions.
76% of participants were reportedly free of opioid withdrawal
symptoms at 24 h and did not seek substances over the
observation period of 72 h. Another 12% were without evidence of withdrawal, but nonetheless chose to resume opioid
use. No further follow-up was reported. A subsequent study
by Brown and Alper (2017) recruited 30 people with DSM IV
opioid dependence who received approximately 12 mg/kg
ibogaine. Detoxiﬁcation and follow-up outcomes were evaluated up to 12 months later using the Subjective Opioid
Withdrawal Scale and the Addiction Severity Index Composite scores. One month after treatment, 15 participants
(50%) reported no opioid use, followed by varying results in
reported opioid use in the months to follow: 10 participants
(33%) after three months, 6 (20%) after six months, 11 (37%)
by 9 months, and 7 (23%) at 12 months. Noller, Frampton,
and Yazar-Klosinski (2017) observed 14 participants with
opioid dependence who independently sought treatment, in
which a staggered ibogaine dose of between 25 and 55 mg/kg
was administered (Noller et al., 2017). The study measured
addiction severity over 12 months as the primary outcome
using the Addiction Severity Index-Lite (ASI-Lite), and secondary effects on depression using the Beck Depression Inventory II (BDI-II). Urine screen results indicated that 75%
of the participants were negative for opioid use after 12
months, while signiﬁcant reductions were also recorded in
the BDI-II scores.
In addition to the observational studies reviewed in this
paper, a systematic review by Dos Santos, Bouso, and Hallak
(2017) identiﬁed four additional studies that further suggested
ibogaine signiﬁcantly reduced opioid withdrawal symptoms,
and that many subjects remained drug-free from 24 h to
weeks or months across the case series. Like the studies
presented in our narrative review, the additional four studies
were limited in that they lacked control groups and placebo,
and most treatments were performed in a non-medical and
unsupervised context with no standardised protocols.
Toxicity. According to a review by Alper, Staajic, and Gill
(2012), data for 19 published human fatalities associated
with the use of ibogaine contribute to concerns about its
clinical use. Ibogaine presents complex pharmacokinetics,

rendering it safest when administered under medical supervision following robust screening. Reports of ibogaine
fatalities often lack information on the quantities of ibogaine
or noribogaine present in the blood during autopsy (for
review, see Alper et al., 2012). In some instances, such as the
New Zealand study where ibogaine was administered to
humans under medical supervision, one person died (Noller
et al., 2017). A number of the human fatalities documented
in the academic literature can be linked to co-consumption
of other substances, including the use of amphetamine or
methamphetamine (Alper, 2001), opioids (Alper & Glick,
1992; Clavey, 2018; Mazoyer et al., 2013) and methadone
(Mazoyer et al., 2013). Further, given that ibogaine is mainly
metabolised by cytochrome P4502D6, some people with
genetic variants of the cytochrome might be at higher risk of
experiencing toxic effects such as those involving the cardiovascular system (for review, see Koenig & Hilber, 2015).
In addition to causing brachycardia, ibogaine interacts with
the cardiac ion channels and these effects likely contribute to
ibogaine’s potentially life-threatening cardiotoxicity. Cardiotoxicity could be as a result of a blockade of the repolarising human ether-a-go-go-related gene (hERG)
potassium channels; retardation of the repolarisation phase
of the ventricular action potential (AC); and concomitant
prolongation of the QT interval in the ECG, ultimately
creating the possibility of life-threatening Torsades de
Pointes (TdP) arrythmias.

The cultural aspects associated with the use of
ibogaine
The origins of ibogaine. In a paper submitted to the
American Anthropological Association, Fernandes (1965)
introduced information gathered in Gabon, Cameroon and
Equatorial Guinea on the Bwiti. Bwiti is considered a
monotheistic universal religion (Samorini, 1993, 1995),
accessible to anyone who approaches it with humility and
respect. It incorporates animism, ancestor worship, Christianity, and a rich history of using the entheogenic substance, iboga (Mash, 2018; Popik et al., 1995). In the
mythology of the Bwiti, iboga is the tree of knowledge of
good and evil, as depicted in the myths of the old testament
of the Bible (Samoniri, 1993).
The use of ibogaine in the traditional context. During the
Christmas and Easter periods, the Bwiti collectively take
iboga over a four-day period as a form of communion
while initiation rites are undertaken by individuals who
have a desire to join the Bwiti. Initiation takes place in four
stages including admission, theory, exercises and practice
(Nyongo-Ndoua & Vaghar, 2018). Prior to the ceremony,
the initiate is expected to abstain from sex and food as part
of the puriﬁcation of the body in preparation (Gollnhofer &
Sillans, 1985). The initiation rite consists of making a
ritualistic offering to the forest and its trees, followed by
confession that concerns the entire past of the initiate to
circumvent what are considered bad thoughts. This is
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followed by taking a much larger dose of iboga than would
normally be consumed during the collective ceremonies. It
consists of a few hectograms of the powdered rootbark,
ingested in smaller quantities over a period of 7–12 h,
lasting three consecutive days and nights (Samorini, 1995).
The initiate remains lying on the ﬂoor and is assisted by
members who represent the mother and father ﬁgures of
the initiation process. Other members may also ingest
iboga during the ceremonies, acting as companions for the
initiate during the journey. Around the third night, an
ofﬁciating member will pierce the initiate with a thorn to
test responsiveness – if the initiate does not react, it is
understood that the person has reached the climax of the
experience. This is considered the moment of illumination
that the initiate receives, a deﬁning moment that must
carry the initiate during future times of difﬁculty (Samorini, 1995).
During the journey, adherents of the Bwiti believe that
the initiate meets with the spirits of the dead who serve as
mediators for encounters with the divine (Mazoyer et al.,
2013). The spirits of the dead also provide an initiatory
name, which is added to the initiate’s proper names. The
Bwiti understand their religion to be one of ongoing
revelation, with new insights being revealed to initiates
during the iboga ritual. Following the journey, the initiate
wakes up to a new life. If the initiate lingers in a state of
lost consciousness, it is understood as a positive sign of
continued communion with the spirits. The Bwiti do not
attribute a ‘bad trip’ to iboga, but rather consider any such
occurrence as due to the impurities and bad thoughts of
the initiate. Once the initiate is awake and has recounted
the experience to the community, the initiate is considered
an initiated member (Samorini, 1993). This ﬁnal step
consists of a ceremonial exit from the sacred space and
presentation to the group (Nyongo-Ndoua & Vaghar,
2018). Following the rite of passage, the new member will
spend a period in isolation where the person is cared for by
a young woman who has recently given birth, as the
member is considered a new-born (Gollnhofer & Sillans,
1983).
From the Bwiti perspective, the contents of the visionary
experience is described in four distinct stages (Gollnhofer &
Sillans, 1985). The ﬁrst stage consists primarily of incoherent
images devoid of religious signiﬁcance, while the second
stage is characterised by a series of apparitions of menacing
looking animals that break apart and form again rapidly.
The third stage progresses to the mythical and the initiate
sees more peaceful and coherent images. The fourth stage is
marked by the encounter with higher spiritual entities. Iboga
is understood by the Bwiti to bring about the visual, tactile
and auditory certainty of the existence of a realm beyond
normal perception. By accessing this realm, the initiate is
believed to belong to two planes between which he or she
blends existence, not knowing where birth and death begin
(Gollnhofer & Sillans, 1983; Nyongo-Ndoua & Vaghar,
2018). Iboga brings about the knowledge of existence on
these planes, and death is understood to be the beginning of
a new existence.
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The psychological aspects of ibogaine
The use of ibogaine as a catalyst for the therapeutic
process. The psychedelic paradigm, as articulated by
Winkelman (2014), refers to the changes in the worldview
and perceptions of individuals following dramatic experiences produced by entheogens. These cathartic, sometimes
mystical, experiences can result in permanent changes in
personality and mood that can positively contribute to
changes in the treatment of substance use disorders (Bright
et al., 2017; Schenberg, 2018; Winkelman, 2014). Entheogenic substances could also lead to a heightened awareness
of the negative consequences of substance use and a sense of
self-liberation and relief.
Schenberg (2018) described the contemporary model of
psychedelic-assisted psychotherapy (PAP). PAP involves
preparatory psychotherapy, followed by a moderate to high
dose of psychedelics in the presence of one or more therapist, followed by integrative psychotherapy. In the case of
ibogaine, Schenberg (2018) notes that psychotherapeutic
models used in the treatment of substance use disorders,
such as individual and group counselling, are often used.
PAP shifts the focus away from the efﬁcacy of the substance
to the efﬁcacy of the contextual experience in which the
emotional, cognitive and behavioural changes take place.
Therapeutic modalities associated with PAP include Motivational Interviewing and Acceptance and Commitment
Therapy (for review, see Schenberg, 2018). A retrospective
analysis of data from 75 people who were previously
dependent on alcohol, cannabis, cocaine HCl and crack
cocaine by Schenberg, de Castro Comis, Chaves, and da
Silveira (2014) found individuals treated with a single dose
of ibogaine reported abstinence for a median of 5.5 months,
while those treated in combination with psychotherapy
remained abstinent for a median of 8.4 months. This ﬁnding
suggests that the combination of ibogaine with psychotherapy can facilitate prolonged periods of abstinence.
Phenomenological analysis of the ibogaine experience. In a
phenomenological analysis of ibogaine experiences, Schenberg et al. (2017) catalogued the experiences of 22 participants into themes. The themes included physical sensations,
perceptual effects, visions, cognitive effects, emotional effects, spiritual phenomena and comparisons to other psychoactive substances. Insights arising included family
dynamics through childhood memories and the emotions
associated with memories; problematic issues in friendships;
and social interactions that contributed to the use of substances or other dysfunctional behaviours. Some participants
also reported insights regarding their role in society, or the
type of career they would like to pursue, while others found
renewed motivation and a sense of purpose in their current
careers. Participants generally also reported a marked
improvement in quality of life, with many citing improved
approaches to nutritional habits and the enjoyment of food.
For others, improved quality of life related to a fundamental
desire to stay alive and to enjoy life more truthfully and
meaningfully.
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In a qualitative study by Kohek, Ohren, Hornby,
Alcazar-Corcoles, and Bouso (2020) exploring the acute
subjective effects of ibogaine among 20 participants, the
researchers proposed similar categories to Schenberg et al.
(2017) with some deviations. The categories included
physical effects, sensory effects, visual effects, cognitive effects, auditory effects, adverse effects, anti-dependency agent
and aftereffects. The visual effects were divided into two
subcategories, namely open eye visuals (OEV) and closed
eye visuals (CEV). CEV were further divided into three
subcategories, namely ancestors and entities; sceneries and
landscapes; and horriﬁc scenarios. Cognitive effects were
also divided into six categories, namely self-psychoanalysis
enhancement; empathy, love and prosocial behaviour;
catharsis; observer quality; ego dissolution (death and
rebirth); and spiritual states.
Ibogaine and REM sleep. Goutarel, Gollnhofer, and Sillans
(1993) hypothesised that the state induced by ibogaine resembles functional aspects shared by the brain states of
Rapid Eye Movement (REM) sleep, including noteworthy
effects on learning and memory. REM sleep is characterised
by the appearance of fast, desynchronised rhythms in the
cortical electroencephalogram (EEG), rapid eye movements,
autonomic activation and loss of muscle tone. Since the
cortical EEG of REM closely resembles that of the waking
state, it has been termed active sleep (Fuller, 2007). During
REM sleep, it is believed that a reconsolidation of learned
information takes place in a state of heightened neural
plasticity, with the reprocessing of previously learned information and the formation of new associations (McNamara & Bulkeley, 2015). The putative link between the
ibogaine state of consciousness and REM is, however,
challenged by a study by Gonzalez et al. (2018) that aimed to
characterise the acute effects of ibogaine on wakefulness and
sleep. The authors concluded that ibogaine produces a
waking state accompanied by robust and long-lasting REM
sleep suppression, thus casting doubt on REM as the
mechanism responsible for insight and the formation of new
associations.
Ibogaine and memory retrieval. Popik (1996) suggested
that ibogaine’s action involving memory retrieval plays an
important role in its use as a treatment for substance use
disorders. Reconsolidation-based interventions offer promising treatment for substance use disorders by disrupting
reconsolidation of maladaptive instrumental and Pavlovian
memories (Milton, 2013). This observation was made
following an experiment with rats in a water maze, which is
a reliable way of assessing the effects of psychoactive substances on spatial learning and memory processes. Under
the inﬂuence of ibogaine, rats demonstrated rapid acquisition of spatial memory.
Rodger (2018) suggested that the experience of retrieving
childhood memories and the creation-migration mythology
experienced by the Bwiti are regressions. These regressions
can be childhood memories, traumatic events or social dynamics that played a role in shaping the perceptions of the
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individual. The ibogaine experience reportedly eliminates
the notion of time as the past, present and future blend into
one. The Bwiti believe this experience to be necessary for the
initiate to return to his birthplace. Individuals who undertake the ibogaine experience often describe it from the
perspective of an observer of the self, seeing different perspectives play out that facilitate a new perspective on the
dynamics of social situations.
Following an open nonblinded study, Regan (1992)
suggested that the psychological mechanisms associated with
the use of ibogaine involve the release of repressed memories, the intellectual re-evaluation of memories, and integration of new insights into the personality of the person.
The ability to integrate new perspectives and reﬂect on the
mental state of the self is called mentalisation (Choi-Kain &
Gunderson, 2008, as cited by Rodger, 2018, p. 93) and has
been demonstrated to be effective in enhancing secure
relational attachments and emotional self-regulation.
Ibogaine in the context of states of consciousness. The
pursuit of non-ordinary states of consciousness is a phenomenon found across time, culture, geographies and even
species. Anthropological reports suggest that non-ordinary
states of consciousness have been an integral part of human
life since the earliest recorded times (Winkelman, 1997).
Weil (1983, as cited in McPeak, Kennedy, and Gordon,
1991) suggested that the experience of non-ordinary states is
so compelling and universal that they are part of the human
experience. Children often freely seek out this experience
through play, such as rolling down a hill or spinning until
they feel dizzy. Even drug rehabilitation programmes such as
Alcoholics Anonymous (AA) direct its members to seek a
change in consciousness, a spiritual awakening (McPeak
et al., 1991). Generally, social disapproval of non-ordinary
states prevail as these are perceived to be dangerous, linked
to depression, psychosis or self-destruction.
A body of work primarily developed by Laughlin
(Laughlin, 2013; Laughlin, McManus, & d’Aquili, 1990;
Laughlin & Throop, 2001) explores the difference between
monophasic and polyphasic cultures. In monophasic cultures, such as those typical of the Western world, children
are taught from a young age to disregard alternative states
such as dreams, and to focus on adaptation to the external
world. Formal and informal education models do not
embrace the individual’s dream life, and information obtained in the dream, which tends to skew the development of
consciousness away from non-ordinary states and towards
perceptual and cognitive processes directed towards
consensus reality. In polyphasic cultures, found in pre-industrial societies, non-ordinary states such as dreams, trance
and meditation states are actively pursued and integrated
into the everyday understanding of the nature of reality. In
polyphasic cultures it is accepted that experiences during
non-ordinary states are an essential part of how an individual’s identity is formed.
The ibogaine state of consciousness is a non-ordinary
state of consciousness. Vaitl et al. (2005) divided non-ordinary states of consciousness into ﬁve categories according to
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how they are induced: spontaneous (day-dreaming and
near-death experiences); physical and physiological (fasting
and sex); psychological (music, meditation and hypnosis),
pathological (epilepsy and brain damage); and pharmacological (psychoactive substances). Non-ordinary states of
consciousness are considered catalysts for transformation.
These experiences are extraordinary and intensely personal,
occurring in unique circumstances that contribute to the
difﬁculty of reproducing and studying them. Grof (2012)
argues that experiencing a non-ordinary state of consciousness has the potential to lead to signiﬁcant insight and
may result in lasting transformation of the self-concept.
Naranjo (1969) used the term oneirophrenia to describe
the ibogaine-induced state of consciousness. Oneirophrenia is
derived from the Greek words oneiros (dream) and phren
(mind) meaning a dream-like state. Popik (1996) described
this state being akin to a dream with full consciousness that is
easily manipulated. Oneirophrenia has also been described as a
hallucinatory state caused by prolonged sleep deprivation or
sensory deprivation. The resulting dream-state does not produce interferences in thinking, identity distortions and spacetime alterations usually associated with hallucinogenic substances (Gonzalez et al., 2018). However, as highlighted by
Alper (2001), the visual or dream-like state is typically only
experienced during the ﬁrst phase of the ibogaine journey. The
visual effects of the ibogaine experience have been characterised as “high density images generally of an autobiographical nature and central to life narrative, although archetypal
and cartoon-like imagery is also reported” (Winkelman, 2014,
p. 106). These visions typically provide psychological insight,
facilitating a level of psychotherapy through evoking repressed
memories, and promoting introspection.

DISCUSSION
Our narrative review of the pharmacological, cultural and
psychological aspects of ibogaine found evidence that each
of these aspects contributed to the effectiveness of ibogaine,
and potentially contribute to its mechanism of action.
Although the exact pharmacological mechanisms for ibogaine are still speculative, there is evidence that ibogaine
interacts with one or more neurotransmitter systems. Ibogaine’s main metabolite, noribogaine, reputed for its longlasting effects that might assist people deal with post-treatment cravings and acting as an antidepressant, also still
requires further investigation. In human trials conducted by
Glue et al. (2015), single oral doses of 3–60 mg of noribogaine was safe and well-tolerated in healthy volunteers.
However, clinical observations by Mash (2018) found that
noribogaine, when administered alone, is ineffective for the
treatment of opioid dependence, suggesting a potentially
important pharmacodynamic interaction between noribogaine and ibogaine. Further understanding about the
psychopharmacology of ibogaine might be gleaned through
research currently underway on 18-MC. 18-MC is being
developed as a non-psychoactive analogue of ibogaine for
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use in opioid detoxiﬁcation. This raises questions around the
role of psychedelic experiences in the context of transformational healing as investigated by Majic, Schmidt, &
Gallinat (2015).
Although preliminary evidence suggests that ibogaine
may be effective in the treatment of opioid use disorder,
further randomised controlled trials are required. Another
area that requires further investigation is ibogaine’s reputed
effect in the treatment of depression as a contributing factor
not only to substance use disorders, but also to mood disorders. Three studies included in this narrative review
(Bastiaans, 2004; Davis et al., 2017; Noller et al., 2017)
indicated varied results regarding the effects of ibogaine on
depression, although this was not the primary objective of
the studies.
Our narrative review suggests that set-and-setting is
given primacy during ingestion of ibogaine in the traditional
context. However, more research is needed to understand
the role of set-and-setting in the ibogaine state of consciousness and how this affects its efficacy in the treatment
of substance use disorders, and the broader therapeutic
application. The hypothesis of set-and-setting was first
formulated by Leary (as cited by Hartogsohn, 2017) and
refers to the psychological, social and cultural parameters
that shape the responses to psychedelic substances. It suggests that the state of consciousness occasioned by psychedelics is, among other factors, a function of both: (i) the set,
which includes the intention, attitude, personality and mood
of the participant, as well as (ii) the setting, which involves
interpersonal, social and environmental aspects associated
with the experience. It also extends to the beliefs, attitudes,
preferences, choices and motivations of individuals undertaking these experiences.
The ibogaine journey within its cultural context remains
a largely unexplored area, apart from the work of Gollnhofer
and Sillans (1985), who categorised experiences into four
phases. Meanwhile, the phenomenology of the journey in
the western context has been explored by both Schenberg
et al. (2017) and Kohek, Ohren, Hornby, Alcazar-Corcoles,
and Bouso (2020), who catalogued experiences into themes.
This raises questions around the worldview of participants,
and whether there are distinct differences in the experiences
of the ibogaine journey as experienced by westerners in a
western context, compared with indigenous participants in
the cultural context, and westerners in the traditional
indigenous context.
From a psychological perspective, there is evidence to
suggest that psychedelic and entheogenic substances enable
the individual to transcend beyond the primary identification with the physical body to experience ego-free states of
existence, and that this perspective leads to psychological
insight. This heightened awareness of self also has the potential to illuminate the negative consequences of substance
use. While definitions of the self-concept vary greatly, there
is evidence to suggest that these cathartic, sometimes
mystical experiences can result in permanent changes in
personality and mood (Grifﬁths, Richards, Johnson,
McCann, & Jesse, 2008; Grifﬁths, Richards, McCann, &
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Jesse, 2006; Naranjo, 1969; Schenberg, 2018; Winkelman,
2014). In the context of ibogaine, by transcending beyond
the primary identiﬁcation with the self, the experience can
make a dysfunctional view of the self-concept visible
through the peak experience. This suggests transformation
of the self-concept, leading to self-acceptance and self-surrender. However, the construction and potential transformation of the self-concept as a result of the ibogaine
journey requires further exploration.
While the term oneirophrenia, as first proposed Naranjo
(1969), might be deemed relevant to the waking dream
aspect of the state induced by ibogaine, the term should be
rejected for two principal reasons. First, the term oneirophrenia is also used to describe prolonged sleep deprivation
or sensory deprivation, which seems inappropriate to the
waking dream phase typically occurring during the ﬁrst few
hours of the ibogaine journey. Further, this is the stage when
participants are in a heightened state of awareness. Moreover, although this stage does contain hypnagogic elements,
the phenomenology of this phase is more complex than
would be suggested by referring to its content as that of a
waking dream. The second reason for rejecting this term is
that it fails to acknowledge the second and third phases of
the ibogaine state, which comprise a substantial portion of
the ibogaine journey. In all, this renders the classiﬁcation of
oneirophrenic inadequate, as it only partially describes the
ibogaine state of consciousness.
Another way to understand the ibogaine state of consciousness is through the lens of holotropic states (Grof,
2016). Holotropic is derived from the Greek words holos
(whole) and trepin, meaning moving towards. Thus, the
implication is that holotropic states are inherently healing.
Holotropic states are characterised by the transformation of
consciousness associated with dramatic perceptual changes
in the senses, often accompanied by intense and unusual
emotions, followed by profound alterations in thought
processes. While in this state, the individual can experience
an invasion of other dimensions that can be intense and
overwhelming, while at the same time remaining fully
orientated with reality. These characteristics correlate not
only with reports of the ibogaine experience, but also with
other psychedelics more broadly.
Sensory changes during holotropic states include significantly transformed visual perception, flooded by images
from the individual’s personal history as well as the individual and collective unconscious (Grof, 2016). Visions
could also include insight into the nature of reality or access
to mythical realms, and holotropic states can be accompanied by other sensory experiences such as physical sensations, smells and auditory experiences, with the latter being
very characteristic of the ibogaine experience. The emotional
tone of holotropic states can vary from ecstatic rapture to
bliss, and feelings of oneness, to terror, anger, despair or
guilt (Grof, 2016). The contents of the holotropic state can
be spiritual or mystical, and the experience of death and
rebirth is common. The state of consciousness experienced
by novice shamans during initiations is holotropic. Holotropic states are also used by more experienced shamans to

facilitate the therapeutic process. This refers to the transformation of the self-concept, including the self-narrative, to
bring about lasting changes in the personality and mood of
the person.
Another significant aspect regarding the parallels between the waking dream state of ibogaine, other psychedelic states and holotropic states is the effect on thought
processes – during this phase of the ibogaine journey
cognition is not impaired, yet it functions in a distinctly
different way compared with ordinary states of consciousness. Holotropic states can bring about profound
psychological insights concerning the personal history and
unconscious dynamics of the individual, while receiving
revelations about various aspects of the nature of reality
that transcend our educational and intellectual background. These aspects align with reports that ibogaine can
result in a change in thought processes, and the emotional
tone of the ibogaine experience, as well as sensory and
auditory experiences, are characteristic of holotropic states.
While numerous means for inducing the holotropic state
are explored by Grof (2016) and Valverde (2015), there are
few explicit tools for measuring holotropic states. One tool
that has been used in holotropic breathwork is the Phenomenology of Consciousness Inventory (Pekala, 1991, as
cited by Rock, Denning, Harris, Clark, & Misso, 2015). We
are currently using this tool to measure the ibogaine
experience and explore its potential classiﬁcation as a
holotropic state.

CONCLUSION
Following the narrative review of the literature on ibogaine,
there is room for exploring, defining and articulating aspects
relating to its physiological mechanisms of action; experiences of participants as they relate to set-and-setting; for
providing a more accurate classification of the ibogaine state
of consciousness; and to explore its therapeutic application.
Ibogaine’s reputation as a treatment for substance use disorder largely stems from observational studies, as well as
preclinical data and data following clinical trials of noribogaine. The observational studies are limited, lacking in
control groups and placebo, with most treatments performed in a non-medical and unsupervised context with no
standard controls. Randomised controlled trials are required
to establish ibogaine’s effectiveness, safety and potential
therapeutic application.
Our review also highlights gaps in the literature
regarding the nature and contents of the ibogaine experience, specifically as it relates to the worldview of the
participant. For example, it is unclear how the set-andsetting of the ibogaine experience influences the efficacy of
the treatment, if at all. There appear to be strong correlations between the ibogaine state of consciousness, the
state of consciousness produced by other psychedelic
substances and holotropic states of consciousness. How
these states of consciousness influence therapeutic
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outcomes for substance use disorders requires further
exploration, and it will be valuable to understand how
these can be distinguished from other non-holotropic,
altered states of consciousness, if at all. Future research
should focus on classifying the specific state of consciousness associated with ibogaine and exploring its role
in the treatment of substance use disorders.
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